Pelthos Therapeutics Inc.
No enriched coverage for $PTHS in the last 7 days.
Pelthos Therapeutics (NYSE American:PTHS) expanded ZELSUVMI's formulary coverage to 127 million lives, adding a major PBM covering 24 million and a regional plan covering 3 million. The treatment, launched in July 2025, now reaches 69% of the commercial market and over 70 million Medicaid lives. ZELSUVMI is approved for molluscum contagiosum in patients aged 1+ years.
Pelthos Therapeutics (PTHS) announced expanded formulary coverage for ZELSUVMI, its topical gel for molluscum contagiosum. The company added 24M covered lives via a major PBM and 3M via a regional health plan, increasing total coverage to 127M commercially insured lives. ZELSUVMI, launched in July 2025, is the first FDA-approved at-home treatment for the skin infection.
Pelthos Therapeutics Inc. (PTHS) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. As described in Item 5.07 below, on September 29, 2026, at the 2026 Annual Meeting of Stockholders (the “Annual Meeting”)
Recent PTHS coverage spans financial news, earnings and insider activity.
In the last 30 days, PTHS insiders filed 3 SEC Form 4 transactions — no purchases and 3 sales ($45K). The most active reporter was Friedberg Ezra M with 1 filing. 100% of those filings were made under pre-arranged Rule 10b5-1 plans.
Expanded coverage is likely to boost sales and improve market sentiment for Pelthos.
Coverage expansion should boost sales and market visibility for ZELSUVMI.
Routine corporate governance filing with modest material impact.
Revenue surge and improved gross-to-net margins suggest upside potential, while continued net loss and cash burn temper expectations.
Pelthos Therapeutics reported Q2 2026 progress for ZELSUVMI, citing a 48% rise in prescription units and an 81.3% unit increase tied to a late-2025 PBM contract. The company expects gross-to-nets to move from 29.6% toward mid-30% and projects XEPI launch in Q1 2027 and Xeglyze in Q3 2027. It also noted a $0.9M inventory write-off and a $5.3M one-time milestone payment.
AlphAI scores every news story that mentions PTHS with an AI model for sentiment and relevance, and aggregates insider trades from Pelthos Therapeutics Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Pelthos Therapeutics (NYSE American:PTHS) expanded ZELSUVMI's formulary coverage to 127 million lives, adding a major PBM covering 24 million and a regional plan covering 3 million. The treatment, launched in July 2025, now reaches 69% of the commercial market and over 70 million Medicaid lives. ZELSUVMI is approved for molluscum contagiosum in patients aged 1+ years.
2 min readPelthos Therapeutics (PTHS) announced expanded formulary coverage for ZELSUVMI, its topical gel for molluscum contagiosum. The company added 24M covered lives via a major PBM and 3M via a regional health plan, increasing total coverage to 127M commercially insured lives. ZELSUVMI, launched in July 2025, is the first FDA-approved at-home treatment for the skin infection.
2 min readPelthos Therapeutics Inc. (PTHS) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. As described in Item 5.07 below, on September 29, 2026, at the 2026 Annual Meeting of Stockholders (the “Annual Meeting”)
1 min readPelthos Therapeutics reported Q2 2026 net product revenue of $15.4M, up 45% from Q1. ZELSUVMI prescriptions rose 48% to 11,925 units. Adjusted EBITDA loss narrowed to $5.7M. The company has $24.2M in cash and plans to launch XEPI and Xeglyze in 2027. COGS included a $900K inventory write-off, and SG&A had a $5.3M milestone payment.
3 min readPelthos Therapeutics reported Q2 2026 progress for ZELSUVMI, citing a 48% rise in prescription units and an 81.3% unit increase tied to a late-2025 PBM contract. The company expects gross-to-nets to move from 29.6% toward mid-30% and projects XEPI launch in Q1 2027 and Xeglyze in Q3 2027. It also noted a $0.9M inventory write-off and a $5.3M one-time milestone payment.
6 min readPelthos Therapeutics Inc. (PTHS) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Pelthos Therapeutics Announces Second Quarter 2026 Financial Results Zelsuvmi ® net product revenue grew 45% to $15.4 million during the second quarter of 2026 from $10.7 million in the first quarter of 2026 11,925 Zelsuvmi units were dispensed by 4,571 unique prescr
6 min readDavis Todd C purchased 35,948 shares of Pelthos Therapeutics Inc. (PTHS) at an average of $27.82 ($27.80–$28.73, $1.00M total) across 2 trades on 2026-06-11.
1 min readPelthos Therapeutics Inc. (NYSE American: PTHS) said CEO Scott Plesha will present at 11:05 a.m. ET and take part in one-on-one investor meetings at the Jefferies Global Healthcare Conference on June 4, 2026 in New York. The company noted investors can arrange meetings via their Jefferies representative.
2 min readFrancis Knuettel II (CFO, Treas & Secty) sold (to issuer) 13,947 shares of Pelthos Therapeutics Inc. (PTHS) on 2026-05-22.
1 min readDURHAM, N.C., Sept. 08, 2025 ( GLOBE NEWSWIRE ) -- Pelthos Therapeutics Inc. PTHS, a biopharmaceutical company ( "Pelthos" or the "Company" ) committed to commercializing innovative therapeutic products for high unmet patient needs, today announced that Scott Plesha, CEO, and Frank Knuettel II, ...
3 min read
